StockData
COMPASS Pathways plc logo

COMPASS Pathways plc (CMPS) stock

CMPSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 1/30
$7.98−0.29 (-3.51%)

Close on Nov 17, 2026Market cap $1.11BP/E –Yield –

COMPASS Pathways operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

COMPASS Pathways's operating income for the twelve months ending Jun 30, 2026 was -$181.76M. For fiscal 2025 it was -$179.04M. The highest annual figure on record is -$21.18M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$179.04M–
FY2024Dec 31, 2024-$178.21M–
FY2023Dec 31, 2023-$136.92M–
FY2022Dec 31, 2022-$110.40M–
FY2021Dec 31, 2021-$83.22M–
FY2020Dec 31, 2020-$51.39M–
FY2019Dec 31, 2019-$21.18M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$52.37M–
Q1 FY2026Mar 31, 2026-$42.90M–
Q4 FY2025Dec 31, 2025-$45.95M–
Q3 FY2025Sep 30, 2025-$40.54M–
Q2 FY2025Jun 30, 2025-$42.93M–
Q1 FY2025Mar 31, 2025-$49.62M–
Q4 FY2024Dec 31, 2024-$48.41M–
Q3 FY2024Sep 30, 2024-$47.90M–
Q2 FY2024Jun 30, 2024-$43.32M–
Q1 FY2024Mar 31, 2024-$38.57M–
Q4 FY2023Dec 31, 2023-$38.41M–
Q3 FY2023Sep 30, 2023-$34.06M–
Q2 FY2023Jun 30, 2023-$32.66M–
Q1 FY2023Mar 31, 2023-$31.79M–
Q4 FY2022Dec 31, 2022-$32.19M–
Q3 FY2022Sep 30, 2022-$25.54M–
Q2 FY2022Jun 30, 2022-$27.26M–
Q1 FY2022Mar 31, 2022-$25.42M–
Q4 FY2021Dec 31, 2021-$28.32M–
Q3 FY2021Sep 30, 2021-$21.77M–
Q2 FY2021Jun 30, 2021-$19.53M–
Q1 FY2021Mar 31, 2021-$13.60M–
Q4 FY2020Dec 31, 2020-$11.52M–
Q3 FY2020Sep 30, 2020-$13.48M–
Q2 FY2020Jun 30, 2020-$17.69M–

More COMPASS Pathways figures

See a number that looks wrong?